TCA Cellular Therapy
TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatments for serious and life-threatening diseases. The company utilizes single or a combination of autologous (patient’s own) adult stem cells to treat various diseases, related to the cardiovascular, nervous, skeletal and muscular systems. Six FDA-approved clinical trials at Phases I, II and/or II/III are underway to treat Heart Disease, Peripheral Vascular Disease (PVD), Peripheral Arterial Disease (PAD), Limb Ischemia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) and Spinal Cord Injuries.
TCA-CT’s adult stem cell research allows us to produce a marketable biological product to regenerate damaged blood vessels and organs. As soon as Phase IIIstudies are completed and approved by the FDA for the United States market, the adult stem cell products developed by TCA-CT will be transplanted into humans as treatments for a variety of diseases.
The U.S. Food and Drug Administration (FDA) has given TCA-CT consent to start several clinical trials to evaluate the effectiveness and safety use of adult stem cell products on patients suffering a variety of diseases.
Once trials have successfully demonstrated that the cell product is safe, effective and does not produce side effects (Phase III), the information will be examined by the FDA and post marketing studies will delineate the utilization of the stem cell product into humans as treatments for specific diseases. Accordingly, TCA-CT anticipates its first marketable biological product for the treatment of severe limb ischemia to be available as early as 2012.